Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Charles Ferté(CentraleSupélec), Jean‐Charles Soria(Inserm), Samy Ammari(Université Paris-Saclay), Nathalie Chaput(Institut Gustave Roussy), Laurent Dercle(Memorial Sloan Kettering Cancer Center), Aurélien Marabelle(Institut Gustave Roussy), Antoine Hollebecque(Institut Gustave Roussy), Christophe Massard(Institut Gustave Roussy), Alexander M.M. Eggermont(University Medical Center Utrecht), Sophie Postel‐Vinay(Université Paris-Sud)
Cited by 1,207
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k